Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. Common Stock (LXEO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · LXEO · as of Mar 31, 2025
Ownership Breakdown
91
Institutional Holders
▲ 2 vs Q4
$100.00M
Total Inst. Value
▼ $94.20M vs Q4
78.52M
Shares Outstanding
freeFloat 60.50%
28.01M
13F Shares Held
▼ 1.51M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
LXEO largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
JANUS HENDERSON GROUP PLC biological products, (no diagnostic substances) | 4.56M | 13.76% | 13.76% | $18.62B | May 15, 2025 | ▲ 218.7K |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 2.72M | 8.22% | 8.22% | $9.45B | May 15, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 1.84M | 5.56% | 5.56% | $6.39B | May 2, 2025 | ▲ 20.3K |
AFFINITY ASSET ADVISORS, LLC biological products, (no diagnostic substances) | 1.48M | 4.47% | 4.47% | $5.14B | May 14, 2025 | NEW |
OMEGA FUND MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.18M | 3.58% | 3.58% | $4.11B | May 15, 2025 | — held |
BLACKSTONE INC. biological products, (no diagnostic substances) | 1.16M | 3.50% | 3.50% | $4.02B | May 15, 2025 | — held |
VESTAL POINT CAPITAL, LP biological products, (no diagnostic substances) | 1.14M | 3.43% | 3.43% | $3.94B | May 15, 2025 | ▼ 63.8K |
NOVO HOLDINGS A/S biological products, (no diagnostic substances) | 1.12M | 3.39% | 3.39% | $3.90B | May 15, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 1.10M | 3.32% | 3.32% | $3.81B | May 9, 2025 | ▼ 19.6K |
POINT72 ASSET MANAGEMENT, L.P. biological products, (no diagnostic substances) | 1.10M | 3.32% | 3.32% | $3.81B | Jul 21, 2025 | ▲ 347.9K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
16
Increased
+1.80M shares9
New Positions
first time holders16
Decreased
−3.70M shares0
Sold Out
fully exitedNet shares change (top 50)
1.90M
+1.80M / −3.70M
Net new holders
+9
9 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
LXEO insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
3
Sell transactions
0.33
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Otero Jose Manuel Chief Operating Officer | May 18, 2026 | Sale | 1,302 | $5.07 | $6.6K | 130.1K | Form 4 ↗ |
Townsend Richard Nolan Chief Executive Officer | May 18, 2026 | Sale | 3,342 | $5.06 | $16.9K | 336.8K | Form 4 ↗ |
Sepp-Lorenzino Laura director | Apr 28, 2026 | Award | 50,000 | $5.81 | $290.5K | 50.0K | Form 4 ↗ |
Townsend Richard Nolan Chief Executive Officer | Apr 6, 2026 | Sale | 55,000 | $5.69 | $313.1K | 340.1K | Form 4 ↗ |
Townsend Richard Nolan Chief Executive Officer | Mar 13, 2026 | Award | 2,623 | $2.64 | $6.9K | 395.1K | Form 4 ↗ |
Otero Jose Manuel Chief Operating Officer | Mar 13, 2026 | Award | 5,930 | $2.64 | $15.7K | 131.4K | Form 4 ↗ |
Otero Jose Manuel Chief Operating Officer | Feb 18, 2026 | Sale | 3,016 | $6.40 | $19.3K | 125.5K | Form 4 ↗ |
Townsend Richard Nolan Chief Executive Officer | Feb 18, 2026 | Sale | 10,173 | $6.38 | $64.9K | 392.5K | Form 4 ↗ |
Otero Jose Manuel Chief Operating Officer | Nov 18, 2025 | Sale | 721 | $9.27 | $6.7K | 63.5K | Form 4 ↗ |
Bhalla Narinder Pal Chief Medical Officer | Feb 13, 2026 | Award | 297,000 | $6.31 | $1.87M | 297.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Lexeo Therapeutics, Inc. Common Stock (LXEO) is primarily owned by institutional investors, who hold approximately 35.7% of total shares outstanding. Company insiders own approximately 39.50%, while retail and public investors account for the remaining 24.83%.
The largest institutional shareholder of Lexeo Therapeutics, Inc. Common Stock is JANUS HENDERSON GROUP PLC, holding approximately 4.56 million shares — equal to 13.76% of outstanding shares — as of March 31, 2025.
A total of 91 institutional investors currently hold LXEO stock, with a combined institutional value of approximately $99,995,692 as of the most recent 13F filing period.
Frequently asked questions
LXEO ownershipLexeo Therapeutics, Inc. Common Stock (LXEO) is primarily owned by institutional investors, who hold approximately 35.7% of shares. The largest shareholder is JANUS HENDERSON GROUP PLC with a 13.76% stake. Company insiders hold 39.50%. Data sourced from SEC Form 13F as of March 31, 2025.